{"id":"NCT00078325","sponsor":"Cephalon","briefTitle":"Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)","officialTitle":"A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-02","primaryCompletion":"2004-11","completion":"2004-11","firstPosted":"2004-02-25","resultsPosted":"2010-07-29","lastUpdate":"2013-07-19"},"enrollment":395,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Obstructive Sleep Apnea","Hypopnea"],"interventions":[{"type":"DRUG","name":"Armodafinil 250 mg/day","otherNames":["NUVIGIL","CEP-10953"]},{"type":"DRUG","name":"Armodafinil 150 mg/day","otherNames":["NUVIGIL","CEP-10953"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSAHS) by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (30-minute version) (average of 4 naps at 0900, 1100, 1300, and 1500) and by Clinical Global Impression of Change (CGI-C) ratings (as related to general condition) at week 12, or last post-baseline visit.","primaryOutcome":{"measure":"Maintenance of Wakefulness Test (MWT)","timeFrame":"change from baseline at 12 weeks","effectByArm":[{"arm":"Armodafinil 250 mg/Day","deltaMin":2.2,"sd":8.07},{"arm":"Armodafinil 150 mg/Day","deltaMin":1.7,"sd":6.49},{"arm":"Placebo","deltaMin":-1.7,"sd":8.59}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0001"},{"comp":"OG001 vs OG002","p":"0.0008"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":131},"commonTop":["Headache","Nausea","Insomnia","Dizziness","Dry Mouth"]}}